CARE Ratings, acting as Monitoring Agency, reports on the utilization of ₹114.30 crore from SMS Pharmaceuticals' rights issue/convertible warrants for the quarter ended 31 December 2025, as per SEBI regulations.
AI Assistant
SMS Pharmaceuticals Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.